NCT05845450View on ClinicalTrials.gov

Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)

PHASE2RecruitingINTERVENTIONAL
Enrollment

140

Participants

Timeline

Start Date

May 11, 2023

Primary Completion Date

May 31, 2026

Study Completion Date

May 31, 2028

Conditions
Colorectal CancerResectable Colorectal Carcinoma
Interventions
DRUG

Trastuzumab deruxtecan

trastuzumab deruxtecan 5.4 mg/kg IV on day 1

DRUG

Durvalumab

durvalumab 1500 mg IV on day 1

DRUG

Panitumumab

panitumumab 6 mg/kg IV on days 1 and 15

DRUG

Botensilimab

botensilimab 1 mg/kg on day 1

DRUG

Balstilimab

balstilimab 3 mg/Kg on days 1 and 15

DRUG

Sotorasib

sotorasib 960 mg orally once daily from day 1 to 28

DRUG

Vorbipiprant

vorbipiprant 90 mg orally bid from day 1 to 28

DRUG

Nivolumab

240 mg IV on days 1 and 15

Trial Locations (1)

20133

RECRUITING

Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan

All Listed Sponsors
lead

Gruppo Oncologico del Nord-Ovest

OTHER